New test set to target growth hormone misuse:
This article was originally published in Clinica
Executive Summary
Researchers have developed an immunoassay that could indicate whether an athlete has misused recombinant human growth hormone (r-hGH). "Doping" has until now been considered undetectable because once injected, r-hGH is identical to a form of naturally occurring pituitary-derived human growth hormone, said the research team, which was led by Dr Christian Strasburger of Innenstadt University Hospital, Munich, Germany. In an assessment of 165 serum samples, the test correctly ruled out everyone who had not used r-hGH, according to a letter published in The Lancet (March 13).
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.